{
    "root": "4bf16775-ab64-4dd5-8a85-15d0bc415f41",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Celecoxib",
    "value": "20210514",
    "ingredients": [
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "Celecoxib is indicated",
    "contraindications": "• Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. (2.1 ) • OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) • RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 )",
    "warningsAndPrecautions": "Celecoxib 50 mg capsules are white, with reverse printed white on red band of body and cap with markings of 7767 on the cap and 50 on the body, supplied as:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Size\n                           \n                        \n                     \n                     \n                        \n                           \n                              59762-1515-1\n                           \n                           \n                              bottle of 60 \n                           \n                        \n                     \n                  \n                  Celecoxib 100 mg capsules are white, with reverse printed white on blue band of body and cap with markings of 7767 on the cap and 100 on the body, supplied as:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Size\n                           \n                        \n                     \n                     \n                        \n                           \n                              59762-1516-1\n                           \n                           \n                              bottle of 100\n                           \n                        \n                        \n                           \n                              59762-1516-3\n                           \n                           \n                              bottle of 500\n                           \n                        \n                     \n                  \n                  Celecoxib 200 mg capsules are white, with reverse printed white on gold band with markings of 7767 on the cap and 200 on the body, supplied as:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Size\n                           \n                        \n                     \n                     \n                        \n                           \n                              59762-1517-1\n                           \n                           \n                              bottle of 100\n                           \n                        \n                        \n                           \n                              59762-1517-3\n                           \n                           \n                              bottle of 500\n                           \n                        \n                     \n                  \n                  Celecoxib 400 mg capsules are white, with reverse printed white on green band with markings of 7767 on the cap and 400 on the body, supplied as:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Size\n                           \n                        \n                     \n                     \n                        \n                           \n                              59762-1518-2\n                           \n                           \n                              bottle of 60",
    "adverseReactions": "Celecoxib is contraindicated in the following patients:\n                  \n                  \n                     \n                        •Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see Warnings and Precautions (5.7, 5.9)\n                        ]. \n                     \n                        •History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [see Warnings and Precautions (5.7, 5.8)\n                        ].\n                     \n                        •In the setting of CABG surgery [see Warnings and Precautions (5.1)\n                        ].\n                     \n                        •In patients who have demonstrated allergic-type reactions to sulfonamides [see Warnings and Precautions (5.7)\n                        ]."
}